ks凯时

The European Commission (EC) Approves Bio-Thera Solutions’ BAT2206 (USYMRO®, ustekinumab), a biosimilar referencing Stelara®

2025-08-26

Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...

查看详情

09-082021

Bio-Thera Solutions Announces Commercialization and License Agreement for BAT1706, a Proposed Biosimilar Referencing Avastin® (Bevacizumab)

®Under the agreement, Bio-Thera will maintain responsibilities for development, manufacturing, and supply of BAT1706. Sa...
08-272021

Bio-Thera Solutions and Hikma Pharmaceuticals announce exclusive commercialization and license agreement for BAT2206 in the US, a proposed biosimilar referencing Stelara® (ustekinumab)

Guangzhou and London, 27 August2021–Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today...
08-122021

Bio-Thera Solutions Announces the First Patient Dosed in Phase III Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab)

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, tod...

上一页 ···20 21 22 23 24 ··· 下一页

微信公众号